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SUMMARY 
A case of an acute dystonic reaction in a child pre-
sumptively treated for malaria with amodiaquine, and a 
case of persistent asymptomatic bradycardia in another 
child with mild pulmonary stenosis treated with a stan-
dard dose of amodiaquine for parasitologically con-
firmed uncomplicated malaria, is reported. Both sub-
jects were homozygous for the wild type allele of cyto-
chrome P450 2C8, the main enzyme responsible for 
amodiaquine metabolism. In both subjects, plasma 
concentrations of N-desethylamodiaquine and N-bis-
desethylamodiaquine, the main metabolites of amo-
diaquine, were normal. No other drugs were detectable 
in the plasma of these two subjects after further toxico-
logical screening. These observations, which suggest 
altered metabolism in the subject with an acute 
dystonic reaction, support the assertion that amo-
diaquine-associated dystonia is an idiosyncratic reac-
tion. However, the occurrence of bradycardia after a 
standard dose of amodiaquine, which coincided with 
the time of expected peak concentrations of the active 
metabolite of amodiaquine, suggests a direct drug ef-
fect. These less reported adverse effects are likely to 
increase in parallel with the increased use of amo-
diaquine as a partner drug for combination therapy of 
malaria in Ghana. Further studies aimed at elucidating 
the mechanisms underlying these effects are, therefore, 
required. 
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INTRODUCTION 
Amodiaquine is a 4-aminoquinoline, which was widely 
used in the past for both prophylaxis and treatment of 
malaria. It was withdrawn from use because of fatal 
side effects, notably agranulocytosis and hepatitis, 
which occurred mainly in non-immune adults taking 
the drug for prophylaxis.1, 2 After oral administration, 
amodiaquine is rapidly metabolized to N-
desethylamodiaquine (DEAQ), the main metabolite 
responsible for the pharmacological effects of the drug, 
as well as other metabolites, such as N bis-
desethylamodiaquine (bis-DEAQ) and hydroxyl-
amodiaquine.3 The main enzyme responsible for the 
conversion of amodiaquine to DEAQ is CYP2C8, a 
polymorphic isoform of hepatic cytochrome p450 2C8, 
whose gene is located on chromosome 10q 24. Amo-
diaquine-associated dystonic reaction was first reported 
from Nigeria in 1976.4 Since then, there has been a 
paucity of similar reports in the published literature 
until recently, when a series of such cases were re-
ported from Cote d’Ivoire (in 2004)5 and from Ghana 
(in 2005).6  
 
The mechanism underlying the well-known side effects 
of amodiaquine (agranulocytosis and hepatitis) is direct 
toxicity7, or immune-mediated hypersensitivity.8 The 
mechanism underlying the less-described side effects 
of amodiaquine, such as dystonia, however, has not 
been elucidated. The reason for the lack of evidence on 
underlying mechanisms for these amodiaquine-
associated adverse effects, other than agranulocytosis 
and hepatitis, may be due in part, to lack of data on 
drug concentration profiles from previous studies, as 
well as lack of data on expression profiles of genes 
coding for enzymes responsible for amodiaquine me-
tabolism.  
 
In this report, two cases of the less-described adverse 
effects of amodiaquine, acute dystonic reaction in a 
child presumptively treated with what was reported to 
be more than several-fold the recommended dose of 
amodiaquine, and persistent asymptomatic bradycardia 
in another child with parasitologically-confirmed un-
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complicated malaria treated with a standard dose of 
amodiaquine, and who was subsequently found to have 
mild pulmonary stenosis, are presented. These observa-




The subject was a three year old, 11.2 kg female re-
ferred to Korle Bu Teaching Hospital (KBTH), Accra, 
with a four-hour history of “restlessness, abnormal 
behaviour and inability to stand or walk”. The patient 
had been seen three days earlier at a polyclinic in Ac-
cra with complaints of fever, anorexia and lethargy, for 
which she was given a three-day course of amo-
diaquine (Enoquine, 50mg/5ml, Ernest Chemists, 
Ghana) to be taken at home. The mother reported ad-
ministering three teaspoonfuls (approximately 150 mg) 
of the drug, three times a day, (instead of once daily), 
for a total of three days.  
 
The child was seen at the Emergency Room of the De-
partment of Child Health, KBTH, with an axillary tem-
perature of 38.20C, inability to respond to verbal re-
quests, an upward moving gaze, protruded tongue, ex-
cessive salivation, and increased muscle tone. A diag-
nosis of an acute dystonic reaction probably due to 
amodiaquine was made.  
 
The peripheral blood film was negative for malaria 
parasites; haemoglobin was 7.9g/dl; total white blood 
cell count was 7.5x109/L, with neutrophil differential 
61.4%; and platelet count was 92x109/L. Blood urea, 
serum electrolytes and creatinine levels were normal. 
The plasma DEAQ concentration measured by a re-
versed phase High Performance Liquid Chromatogra-
phy (HPLC) was 153 ng/ml on presentation, and 110 
ng/ml three days later. A comparison of the ultraviolet 
(UV) spectrum from the HPLC with a UV spectra li-
brary containing 2682 toxicologically relevant sub-
stances9 did not show any other drugs in the plasma.  
 
A polymerase chain reaction-restriction fragment 
polymorphism (PCR-RFLP) method10 was used to 
genotype polymorphisms in the CYP2C8 gene. This 
showed the subject to be of the 2C8*1 (wild type) vari-
ant. The symptoms improved upon administration of 
diazepam (3mg stat dose) and intravenous fluids (0.18 
Saline in 4.3% dextrose solution). She made an un-
eventful recovery and was discharged two days later. 
She remained well at follow up one week later.  
 
Case 2 
The subject was a 12-year old, 35kg female who par-
ticipated in a clinical trial of antimalarial drugs. She 
presented with a four-day history of fever, chills, vom-
iting, abdominal pain and an axillary temperature of 
39.40C. She denied intake of any drugs prior to presen-
tation and her past medical history was unremarkable. 
On presentation, her blood pressure was, 110mmHg, 
apex beat was palpable in the 5th left intercostal space 
in the mid-clavicular line, she was not cyanosed, and 
there was no peripheral oedema.  
 
Laboratory investigation showed P. falciparum parasi-
taemia of parasite density 69,654/µL; haemoglobin, 12 
g/dL; total white blood cell count, 5.7 x 109/L, and a 
neutrophil differential count of 64%. Urine microscopy 
and culture, blood urea and serum electrolytes, and 
chest radiograph were normal. An initial electrocardi-
ography (ECG) done as part of the clinical trial investi-
gations showed sinus rhythm, with a ventricular rate of 
103 beats per minute and a rate-corrected QT interval 
(QTc) of 395 ms. Amodiaquine (Camoquine; Pfizer, 
Dakar, Senegal), 10mg/kg body weight, single oral 
daily dose, was administered under supervision for 
three days, with acetaminophen, 15mg/kg body weight 
(one and a half tablets), three times daily. On the sec-
ond day of treatment, a repeat blood smear (tempera-
ture 36.5 0C) showed P falciparum asexual parasitae-
mia of 480/µL. On auscultation on this day, a grade 2/6 
ejection systolic murmur, which was heard best in the 
2nd left intercostal space at the left sternal border, and 
which radiated towards the left shoulder, was audible. 
The blood film was negative on the third day of treat-
ment, but the ECG-measured heart rate was 49 
beats/min (axillary temperature was 36.50C). Echocar-
diography, which was done because of the audible 
heart murmur, reported “mild pulmonary stenosis”.  
 
DEAQ concentrations were 130ng/ml, 110ng/ml, 
38ng/ml, and 9ng/ml in plasma samples taken 3, 7, 14, 
and 28 days post-treatment. Plasma concentrations of 
bis-DEAQ, were 25ng/ml, 10ng/ml and 5ng/ml in sam-
ples taken 7, 14 and 28 days post-treatment. The 
plasma concentrations of DEAQ and bis-DEAQ were 
both below the limit of quantification in plasma sam-
ples taken 33 and 47 days post-treatment. There was no 
detectable amodiaquine, DEAQ, or bis-DEAQ in the 
pre-treatment sample. The subject was homozygous for 
the 2C8*1 variant and further toxicological screening 
did not detect any other drugs in plasma, except aceta-
minophen. Bradycardia persisted through the next six 
weeks. She complained occasionally of easy fatigabil-
ity, but there were no complaints of dizziness, chest 
pain, or shortness of breath. On the 84th and 92nd days 
after recruitment, a heart rate of 64 and 72 beats per 
minute respectively were recorded on the ECG. She 










There is little information on the possible mechanisms 
that may underlie amodiaquine-associated adverse ef-
fects, despite the relatively long history of use of this 
drug. Amodiaquine-associated dystonic reaction was 
first reported by Akindele, who suggested that this is 
an idiosyncratic reaction.4 Although the pharmacoki-
netics of amodiaquine is known to exhibit wide inter-
individual variation11, the finding of normal12 plasma 
DEAQ levels, despite reported intake of several fold 
the recommended therapeutic dose of amodiaquine in a 
subject with wild type CYP2C8, supports the assertion 
of idiosyncrasy.  
 
The mechanism underlying amodiaquine-associated 
dystonic reactions may also be similar to that of 
chloroquine-associated dystonia, which has been linked 
to reduction in fore-brain catecholamine levels and 
inhibition of neuronal calcium uptake.13 This assertion 
could be supported in part, by the observed effective-
ness and symptom reversal of the dystonia by diaze-
pam: it has been proposed that stimulation of the ben-
zodiazepine receptors coupled to the γ-amino butyric 
acid (GABA) receptors via the chloride ion channel in 
the central nervous system facilitate GABA transmis-
sion, with a consequent inhibitory effect on muscle 
hypertonia and tremors. Other possible mechanisms 
that may underlie amodiaquine-associated adverse ef-
fects could be related to, CYP1A1 or 1B1-mediated 
extrahepatic metabolism of amodiaquine3, or biotrans-
formation to chemically reactive electrophilic 
quinoneimine metabolites which, by forming immuno-
genic complexes, may lead to organ-specific toxicity in 
susceptible individuals.   
 
Sinus bradycardia, which may occur during fever reso-
lution in malaria, has been reported after amodiaquine 
treatment in malaria patients with or without fever.14 
Although falciparum malaria itself is known to be as-
sociated with electrophysiological changes in the heart 
- independent of antimalarial drug intake15, amo-
diaquine is known to slow cardiac conduction16, 17, and 
to cause bradycardia, in animals.18 In the second sub-
ject described in this report, the first recording of bra-
dycardia coincided with the time of expected peak cu-
mulative plasma concentration of DEAQ19, strongly 
suggesting the possibility of a direct drug effect. The 
presence of the mild pulmonary stenosis may be a co-
incidental finding.  
 
It is also possible that this underlying cardiac disorder 
– albeit mild and previously undiagnosed – could have 
altered the predisposition of the subject to adverse car-
diovascular effects of amodiaquine. There are currently 
many reports of clinical trials involving amodiaquine, 
but few reports on amodiaquine-associated cardiovas-
cular effects are available. It may, therefore, be impor-
tant to pay particular attention to patients with underly-
ing cardiovascular disease who are on treatment with 
amodiaquine-based regimens. It would be useful also, 
to include cardiac assessment in the post-marketing 
surveillance of amodiaquine-containing regimens. Fur-
ther studies aimed at elucidating the mechanisms un-
derlying these effects, especially within the context of 
the use of amodiaquine as a partner drug in combina-
tion therapy, would especially be desirable.   
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